Ali F. Abdelwahed

Array ( [id] => 19319566 [patent_doc_number] => 20240241109 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-07-18 [patent_title] => Methods to Identify Mutation Specific B Cells and Restore Therapeutic Antibody Efficacy Against Viral Variants [patent_app_type] => utility [patent_app_number] => 18/405350 [patent_app_country] => US [patent_app_date] => 2024-01-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13071 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 90 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18405350 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19158148 [patent_doc_number] => 20240150855 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-05-09 [patent_title] => METHODS AND COMPOSITIONS FOR IDENTIFYING VIRAL SEQUENCES [patent_app_type] => utility [patent_app_number] => 18/506464 [patent_app_country] => US [patent_app_date] => 2023-11-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 94917 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18506464 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19462509 [patent_doc_number] => 20240316178 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-09-26 [patent_title] => RECOMBINANT PROTEIN VACCINES FORMULATED WITH ENANTIO-SPECIFIC CATIONIC LIPID R-DOTAP AND METHODS OF USE THEREOF [patent_app_type] => utility [patent_app_number] => 18/382979 [patent_app_country] => US [patent_app_date] => 2023-10-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14426 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18382979 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19035588 [patent_doc_number] => 20240085403 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-03-14 [patent_title] => METHOD FOR INHIBITING ADVENTITIOUS VIRAL INFECTION [patent_app_type] => utility [patent_app_number] => 18/450554 [patent_app_country] => US [patent_app_date] => 2023-08-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 24024 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -41 [patent_words_short_claim] => 17 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18450554 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18938202 [patent_doc_number] => 20240033341 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-02-01 [patent_title] => HIV VACCINE IMMUNOGENS [patent_app_type] => utility [patent_app_number] => 18/340008 [patent_app_country] => US [patent_app_date] => 2023-06-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 52322 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18340008 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19657015 [patent_doc_number] => 20240424080 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-12-26 [patent_title] => Multi-Epitope Vaccine Platform [patent_app_type] => utility [patent_app_number] => 18/338054 [patent_app_country] => US [patent_app_date] => 2023-06-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6223 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 119 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18338054 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19032570 [patent_doc_number] => 20240082385 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-03-14 [patent_title] => RSV VACCINES AND METHODS OF ADMINISTERING SAME [patent_app_type] => utility [patent_app_number] => 18/202836 [patent_app_country] => US [patent_app_date] => 2023-05-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21306 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 145 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18202836 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18727117 [patent_doc_number] => 20230341398 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-10-26 [patent_title] => SARS-CoV-2 DETECTION KIT AND SARS-CoV-2 DETECTION METHOD [patent_app_type] => utility [patent_app_number] => 18/318892 [patent_app_country] => US [patent_app_date] => 2023-05-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13674 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 70 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18318892 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18879443 [patent_doc_number] => 20240002812 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-01-04 [patent_title] => METHODS OF PREPARING GENE THERAPIES [patent_app_type] => utility [patent_app_number] => 18/319350 [patent_app_country] => US [patent_app_date] => 2023-05-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19411 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18319350 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19557764 [patent_doc_number] => 20240369556 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-11-07 [patent_title] => ISOLATED MONOCLONAL ANTIBODY, ISOLATED ANTIGEN BINDING FRAGMENT THEREOF, COMPOSITION, METHOD OF ELICITING IMMUNE RESPONSE AGAINST ANTIGENIC EPITOPE OF FLAVIVIRUS IN SUBJECT, METHOD FOR DETECTING FLAVIVIRUS, POLYPEPTIDE, AND ANTIBODY-CELL CONJUGATION [patent_app_type] => utility [patent_app_number] => 18/312737 [patent_app_country] => US [patent_app_date] => 2023-05-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 3506 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 45 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18312737 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18597695 [patent_doc_number] => 20230272493 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-08-31 [patent_title] => VIRAL AND HOST BIOMARKERS FOR DETECTION, THERAPEUTIC EFFECTIVENESS, AND MONITORING OF CANCER LINKED TO SARS-CoV-2 AND HUMAN PAPILLOMA VIRUS [patent_app_type] => utility [patent_app_number] => 18/135484 [patent_app_country] => US [patent_app_date] => 2023-04-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16749 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 121 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18135484 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18693096 [patent_doc_number] => 20230323488 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-10-12 [patent_title] => RAPID AND LOW-COST SAMPLING FOR DETECTION OF AIRBORNE SARS-COV-2 IN DEHUMIDIFIER CONDENSATE [patent_app_type] => utility [patent_app_number] => 18/298540 [patent_app_country] => US [patent_app_date] => 2023-04-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9317 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 48 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18298540 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19359356 [patent_doc_number] => 20240261390 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-08-08 [patent_title] => VACCINE FOR PREVENTION OR TREATMENT OF VIRAL INFECTION [patent_app_type] => utility [patent_app_number] => 18/563019 [patent_app_country] => US [patent_app_date] => 2022-05-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11141 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 50 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18563019 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19319579 [patent_doc_number] => 20240241122 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-07-18 [patent_title] => ANTI-NOROVIRUS ANTIBODY [patent_app_type] => utility [patent_app_number] => 18/562053 [patent_app_country] => US [patent_app_date] => 2022-05-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4346 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -7 [patent_words_short_claim] => 33 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18562053 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19297714 [patent_doc_number] => 20240226280 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-07-11 [patent_title] => IMMUOGENIC COMPOSITIONS OF MUTANT SARS-COV-2 N PROTEIN AND GENE AND METHODS OF USE THEREOF [patent_app_type] => utility [patent_app_number] => 18/559272 [patent_app_country] => US [patent_app_date] => 2022-05-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16830 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 45 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18559272 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20033301 [patent_doc_number] => 20250171523 [patent_country] => US [patent_kind] => A9 [patent_issue_date] => 2025-05-29 [patent_title] => CAMELID ANTI-SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS ANTIBODIES [patent_app_type] => utility [patent_app_number] => 18/286852 [patent_app_country] => US [patent_app_date] => 2022-04-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16346 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -22 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18286852 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20033301 [patent_doc_number] => 20250171523 [patent_country] => US [patent_kind] => A9 [patent_issue_date] => 2025-05-29 [patent_title] => CAMELID ANTI-SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS ANTIBODIES [patent_app_type] => utility [patent_app_number] => 18/286852 [patent_app_country] => US [patent_app_date] => 2022-04-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16346 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -22 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18286852 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19497654 [patent_doc_number] => 20240336672 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-10-10 [patent_title] => HUMAN NEUTRALIZING MONOCLONAL ANTIBODIES AGAINST SARS-COV-2 AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 18/288115 [patent_app_country] => US [patent_app_date] => 2022-04-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 53022 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -23 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18288115 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19216337 [patent_doc_number] => 20240181041 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-06-06 [patent_title] => Adenovirus SARS-CoV-2 Vaccine [patent_app_type] => utility [patent_app_number] => 18/282029 [patent_app_country] => US [patent_app_date] => 2022-03-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 36285 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -36 [patent_words_short_claim] => 24 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18282029 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20218669 [patent_doc_number] => 20250281600 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-09-11 [patent_title] => NOVEL COMPOSITIONS OF MATTER COMPRISING STABILIZED CORONAVIRUS ANTIGENS AND THEIR USE [patent_app_type] => utility [patent_app_number] => 18/277921 [patent_app_country] => US [patent_app_date] => 2022-02-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11779 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18277921 [rel_patent_id] =>[rel_patent_doc_number] =>)